Logo image of AGLE

AEGLEA BIOTHERAPEUTICS INC (AGLE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AGLE - US00773J2024 - Common Stock

12.01 USD
+0.97 (+8.79%)
Last: 11/27/2023, 8:00:00 PM
11.88 USD
-0.13 (-1.08%)
After Hours: 11/27/2023, 8:00:00 PM
Fundamental Rating

2

AGLE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of AGLE is average, but there are quite some concerns on its profitability. AGLE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGLE had negative earnings in the past year.
In the past year AGLE has reported a negative cash flow from operations.
In the past 5 years AGLE always reported negative net income.
AGLE had a negative operating cash flow in each of the past 5 years.
AGLE Yearly Net Income VS EBIT VS OCF VS FCFAGLE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

AGLE's Return On Assets of -142.03% is on the low side compared to the rest of the industry. AGLE is outperformed by 86.38% of its industry peers.
AGLE has a worse Return On Equity (-207.78%) than 73.59% of its industry peers.
Industry RankSector Rank
ROA -142.03%
ROE -207.78%
ROIC N/A
ROA(3y)-75.94%
ROA(5y)-75.79%
ROE(3y)-100.98%
ROE(5y)-99.79%
ROIC(3y)N/A
ROIC(5y)N/A
AGLE Yearly ROA, ROE, ROICAGLE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

AGLE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGLE Yearly Profit, Operating, Gross MarginsAGLE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

AGLE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGLE has more shares outstanding
AGLE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AGLE Yearly Shares OutstandingAGLE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
AGLE Yearly Total Debt VS Total AssetsAGLE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -6.87, we must say that AGLE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AGLE (-6.87) is worse than 71.76% of its industry peers.
AGLE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.87
ROIC/WACCN/A
WACC11.07%
AGLE Yearly LT Debt VS Equity VS FCFAGLE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

AGLE has a Current Ratio of 4.59. This indicates that AGLE is financially healthy and has no problem in meeting its short term obligations.
AGLE has a Current ratio (4.59) which is in line with its industry peers.
AGLE has a Quick Ratio of 4.59. This indicates that AGLE is financially healthy and has no problem in meeting its short term obligations.
AGLE has a Quick ratio (4.59) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 4.59
AGLE Yearly Current Assets VS Current LiabilitesAGLE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AGLE have decreased strongly by -111.72% in the last year.
The Revenue for AGLE has decreased by -81.72% in the past year. This is quite bad
Measured over the past years, AGLE shows a very negative growth in Revenue. The Revenue has been decreasing by -14.87% on average per year.
EPS 1Y (TTM)-111.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.63%
Revenue 1Y (TTM)-81.72%
Revenue growth 3YN/A
Revenue growth 5Y-14.87%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 12.22% on average over the next years. This is quite good.
Based on estimates for the next years, AGLE will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y78.51%
EPS Next 2Y38.08%
EPS Next 3Y22.59%
EPS Next 5Y12.22%
Revenue Next Year-43.28%
Revenue Next 2Y144.34%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AGLE Yearly Revenue VS EstimatesAGLE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2030 20M 40M 60M
AGLE Yearly EPS VS EstimatesAGLE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGLE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGLE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGLE Price Earnings VS Forward Price EarningsAGLE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGLE Per share dataAGLE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as AGLE's earnings are expected to grow with 22.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.08%
EPS Next 3Y22.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGLE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEGLEA BIOTHERAPEUTICS INC

NASDAQ:AGLE (11/27/2023, 8:00:00 PM)

After market: 11.88 -0.13 (-1.08%)

12.01

+0.97 (+8.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)03-04 2024-03-04/amc
Inst Owners1301.93%
Inst Owner Change-0.03%
Ins Owners93.41%
Ins Owner Change0%
Market Cap48.04M
Revenue(TTM)1.06M
Net Income(TTM)-294.43M
Analysts82.22
Price Target17.85 (48.63%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-893.9%
Min EPS beat(2)-983.65%
Max EPS beat(2)-804.14%
EPS beat(4)1
Avg EPS beat(4)-446.24%
Min EPS beat(4)-983.65%
Max EPS beat(4)11.76%
EPS beat(8)3
Avg EPS beat(8)-220.54%
EPS beat(12)4
Avg EPS beat(12)-150.49%
EPS beat(16)8
Avg EPS beat(16)-109.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.41%
PT rev (3m)2400%
EPS NQ rev (1m)65.46%
EPS NQ rev (3m)-766.67%
EPS NY rev (1m)84.79%
EPS NY rev (3m)-2071.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)40.74%
Revenue NY rev (3m)533.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 45.32
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-60.34
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)-21.75
FCFYN/A
OCF(TTM)-21.75
OCFYN/A
SpS0.27
BVpS35.42
TBVpS35.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -142.03%
ROE -207.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.94%
ROA(5y)-75.79%
ROE(3y)-100.98%
ROE(5y)-99.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 4.59
Altman-Z -6.87
F-Score2
WACC11.07%
ROIC/WACCN/A
Cap/Depr(3y)155.54%
Cap/Depr(5y)193.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-111.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-96.63%
EPS Next Y78.51%
EPS Next 2Y38.08%
EPS Next 3Y22.59%
EPS Next 5Y12.22%
Revenue 1Y (TTM)-81.72%
Revenue growth 3YN/A
Revenue growth 5Y-14.87%
Sales Q2Q%-100%
Revenue Next Year-43.28%
Revenue Next 2Y144.34%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-156.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.66%
OCF growth 3YN/A
OCF growth 5YN/A

AEGLEA BIOTHERAPEUTICS INC / AGLE FAQ

Can you provide the ChartMill fundamental rating for AEGLEA BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to AGLE.


What is the valuation status of AEGLEA BIOTHERAPEUTICS INC (AGLE) stock?

ChartMill assigns a valuation rating of 1 / 10 to AEGLEA BIOTHERAPEUTICS INC (AGLE). This can be considered as Overvalued.


What is the profitability of AGLE stock?

AEGLEA BIOTHERAPEUTICS INC (AGLE) has a profitability rating of 0 / 10.


How financially healthy is AEGLEA BIOTHERAPEUTICS INC?

The financial health rating of AEGLEA BIOTHERAPEUTICS INC (AGLE) is 6 / 10.


Can you provide the expected EPS growth for AGLE stock?

The Earnings per Share (EPS) of AEGLEA BIOTHERAPEUTICS INC (AGLE) is expected to grow by 78.51% in the next year.